{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-22-000016","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.981594+00:00","generated_at":"2026-06-24T07:16:46.580250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edwards Q2 sales flat at $1.37B; lowers FY2022 outlook on FX, staffing","bullets":["Q2 sales $1.37B flat YoY; underlying growth 5%. GAAP EPS $0.65, adjusted EPS $0.63.","TAVR sales $907M (+1% reported, +5% underlying); TMTT $28M; Surgical $229M; Critical Care $211M.","Full-year sales guidance lowered to $5.35-$5.55B; adjusted EPS guided to low end of $2.50-$2.65.","Q2 share repurchases of $355M; Board approved new authorization with $1.9B remaining.","Adjusted gross margin improved to 80.5% from 75.9%, helped by FX hedge gains."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-22-000016","json":"https://secwatch.observer/filing/0001099800-22-000016.json","markdown":"https://secwatch.observer/filing/0001099800-22-000016.md","text":"https://secwatch.observer/filing/0001099800-22-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000016/0001099800-22-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000016/ew-20220728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:16:46.580250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}